LivaNova PLC (NASDAQ:LIVN) Receives $69.17 Consensus Target Price from Analysts

LivaNova PLC (NASDAQ:LIVN) has received a consensus recommendation of “Buy” from the seven ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $69.17.

LIVN has been the topic of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a report on Tuesday, January 28th. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Mizuho cut their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. Finally, Robert W. Baird upped their price target on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This represents a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.27% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in LivaNova by 12.7% during the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock worth $108,823,000 after acquiring an additional 265,291 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in shares of LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock valued at $109,914,000 after buying an additional 806,374 shares in the last quarter. Capital Research Global Investors boosted its holdings in shares of LivaNova by 19.1% in the 4th quarter. Capital Research Global Investors now owns 1,612,818 shares of the company’s stock valued at $74,690,000 after buying an additional 258,730 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of LivaNova by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after buying an additional 8,331 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of LivaNova by 8.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company’s stock valued at $60,710,000 after buying an additional 107,693 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Trading Down 1.1 %

Shares of LIVN opened at $47.44 on Friday. LivaNova has a twelve month low of $43.15 and a twelve month high of $64.47. The company has a market cap of $2.58 billion, a P/E ratio of 112.95 and a beta of 1.00. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The company’s fifty day simple moving average is $47.95 and its 200-day simple moving average is $49.54.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.